Diagnosis, Treatment, and Outcomes of Males with Central Precocious Puberty

• Renée Robilliard ^[1] ; Peter A. Lee ^[2] ; Lisa Swartz Topor ^[1]
  1. [1] Division of Pediatric Endocrinology and Diabetes, Hasbro Children's Hospital, Providence, RI, USA; Warren Alpert Medical School of Brown University, Providence, RI, USA.
  2. [2] Division of Pediatric Endocrinology, Department of Pediatrics, Penn State College of Medicine, Hershey, PA, USA
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 53, Nº. 2, 2024, págs. 239-250
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Central precocious puberty (CPP) among males is less frequent than among females but more likely to have an underlying pathologic cause. Diagnosis of CPP is often straightforward among males because increased testicular volume, the first sign of puberty, can be verified although careful central nervous system (CNS) assessment is generally necessary. Treatment with gonadotropin-releasing hormone agonist (GnRHa) is indicated, given in conjunction with any therapy needed for CNS lesions. Monitoring of treatment usually can consist of evaluating growth and physical puberty and with testosterone levels as the only lab data. Short-term and long-term outcome data indicate efficacy and safety, although data are limited. Such data need to be reported.